Business, energy, technology, markets and global industry news from Business News Today

Cleerly

PharmaDeviceNews Cleerly
Representative image of cardiovascular drug research and RNA-based therapeutic development. Ribo’s RBD1119 Phase 2 filing highlights growing interest in siRNA antithrombotic strategies for coronary artery disease.
Medical Devices & Diagnostics

Cleerly’s AI can quantify coronary plaque. Can 530-patient PARAMOUNT prove it changes care?

Cleerly's 530-patient PARAMOUNT trial will reveal whether AI-QCT changes stable chest pain management. Examine the evidence and adoption stakes.

Read More
Medical Devices & Diagnostics

Can Cleerly’s AI platform replace invasive IVUS? INVICTUS registry data suggest noninvasive parity

Cleerly's INVICTUS registry shows AI-QCT matches IVUS in coronary plaque quantification. Read the clinical analysis.

Read More